Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 9563I MaxCyte, Inc. 02 April 2024 MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) Be Biopharma to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell
RNS Number : 8379I MaxCyte, Inc. 02 April 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , April 2, 2024 : MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies
RNS Number : 6067H MaxCyte, Inc. 20 March 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options, RSUs and PSUs and PDMR Dealing Rockville, Maryland - 20 March 2024: MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
RNS Number : 6045H MaxCyte, Inc. 20 March 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options, RSUs and PSUs and PDMR Dealing Rockville, Maryland - 20 March 2024: MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
RNS Number : 6065G MaxCyte, Inc. 13 March 2024 MaxCyte announces filing of Form 10-K for the full year period ended December 31, 2023 ROCKVILLE, MD , March 13, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 6063G MaxCyte, Inc. 13 March 2024 MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance ROCKVILLE, MD , March 13, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
ROCKVILLE, Md., March 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative
RNS Number : 8003F MaxCyte, Inc. 06 March 2024 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 5458F MaxCyte, Inc. 05 March 2024 MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results ROCKVILLE, MD , March 5, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
